Trials / Completed
CompletedNCT00871403
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib and pemetrexed | oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily |
| DRUG | pemetrexed and cisplatin | pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2009-03-30
- Last updated
- 2013-06-20
- Results posted
- 2012-02-16
Locations
2 sites across 2 countries: Denmark, United Kingdom
Source: ClinicalTrials.gov record NCT00871403. Inclusion in this directory is not an endorsement.